Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Halozyme ( (HALO) ) just unveiled an announcement.
On November 12, 2025, Halozyme Therapeutics completed the sale of $1.5 billion in convertible senior notes, divided equally between notes due in 2031 and 2032. The proceeds will be used for capped call transactions, repurchasing existing notes, and general corporate purposes, potentially impacting the company’s financial flexibility and market positioning.
The most recent analyst rating on (HALO) stock is a Buy with a $92.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s strong financial performance and positive earnings call are the primary drivers of its high score. The company’s robust revenue growth and raised guidance reflect confidence in its strategic direction. Technical analysis presents mixed signals, and while the valuation is reasonable, high leverage remains a risk.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative products and therapies. The company is known for its proprietary enzyme technology that enhances the delivery of biologics, making it a significant player in the drug delivery market.
Average Trading Volume: 2,169,956
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8B
For a thorough assessment of HALO stock, go to TipRanks’ Stock Analysis page.